630 Oncologists' perspectives on evolution of first-line immune checkpoint inhibitor maintenance therapy in management of advanced urothelial carcinoma in the US

• Petros Grivas,
• Jane Chang,
• Kevin Chiu,
• Murtuza Bharmal,
• Phani Veeranki,
• Vivek Pawar

Affiliations

Petros Grivas

Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA

Jane Chang

Pfizer Inc, New York, NY.

Kevin Chiu

3PRECISIONheor, Los Angeles, CA, USA, Los Angeles, CA, United States

Murtuza Bharmal

7EMD Serono, Billerica, MA, USA, Billerica, MA, United States

Phani Veeranki

2PRECISIONheor, Los Angeles, CA, USA (At the time of the study), Los Angeles, CA, United States

Vivek Pawar

4EMD Serono, Billerica, MA, USA, Billerica, MA, United States